US WorldMeds completed the acquisition of Tecelra from Adaptimmune Therapeutics for $85m.

US WorldMeds, a pharmaceutical company, completed the acquisition of Tecelra, a medicine called a genetically modified autologous T cell immunotherapy from Adaptimmune Therapeutics for $85m. "With the transaction now complete, we are excited to officially welcome Adaptimmune's programs and people into our organization. We are committed to building on the strong foundation Adaptimmune has established and advancing these therapies to bring lasting impact to patients with high unmet needs," Breck Jones, US WorldMeds CEO.